Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cartesian Therapeutics (RNAC) Shares Outstanding (Weighted Average) (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Shares Outstanding (Weighted Average) for 11 consecutive years, with $26.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 50.34% to $26.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $26.0 million, a 50.34% increase, with the full-year FY2025 number at $26.0 million, up 50.34% from a year prior.
  • Shares Outstanding (Weighted Average) was $26.0 million for Q4 2025 at Cartesian Therapeutics, roughly flat from $26.0 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $152.8 million in Q3 2022 to a low of $5.1 million in Q1 2023.
  • A 5-year average of $60.1 million and a median of $26.0 million in 2025 define the central range for Shares Outstanding (Weighted Average).
  • Peak YoY movement for Shares Outstanding (Weighted Average): tumbled 96.64% in 2023, then soared 378.44% in 2025.
  • Cartesian Therapeutics' Shares Outstanding (Weighted Average) stood at $114.3 million in 2021, then rose by 26.62% to $144.8 million in 2022, then crashed by 96.43% to $5.2 million in 2023, then skyrocketed by 234.15% to $17.3 million in 2024, then surged by 50.34% to $26.0 million in 2025.
  • Per Business Quant, the three most recent readings for RNAC's Shares Outstanding (Weighted Average) are $26.0 million (Q4 2025), $26.0 million (Q3 2025), and $25.9 million (Q2 2025).